deltatrials
Completed PHASE3 NCT00069745

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

A Multi-National Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen

Sponsor: Agennix

Conditions Hormone Refractory Prostate Cancer Prostate Cancer
Interventions Prednisone Satraplatin
Updated 8 times since 2017 Last updated: Aug 1, 2012 Started: Sep 30, 2003 Primary completion: Jan 31, 2006 Completion: Mar 31, 2007

A PHASE3 clinical study on Hormone Refractory Prostate Cancer and Prostate Cancer, this trial is completed. The trial is conducted by Agennix and has accumulated 8 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Sep 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Agennix
Data source: Agennix

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany, Aberdeen, United Kingdom, Abilene, United States, Albany, United States, Albuquerque, United States, Altamonte Springs, United States, Amsterdam, Netherlands, Arlington, United States, Armonk, United States, Austin, United States and 170 more location s